Oral GLP-1 medications may be a reasonable option for: Patients early in their weight loss journey Patients with mild to moderate weight loss goals Patients who strongly prefer to avoid injections They may be less ideal for: Patients who have had bariatric surgery Patients needing significant weight loss Patients who have not responded to oral medications in the past The decision is not just about preference
He filed a lawsuit against Novo Nordisk in December 2023
Arumugan K, Yip YC, Sekaran M: Free radicals reactions, lipid peroxides and pelvic pain
Conversely, alteration of the gut microbiota nullifies exercise capacity in the same manner as peripheral endocannabinoid receptor inhibition, ablation of spinal afferent neurons, or dopamine blockade [15]
The theoretical efficacy concern grows here, dropping to roughly 75% of standard dosing based on modeling
Areas requiring further investigation include: Effects on Growth and Development Adolescence is a critical period for growth, and concerns exist regarding the long-term impact of GLP-1RAs on bone development and muscle mass